SQZ Biotech has a promising new way of transforming cell behavior. This technology from MIT’s storied Langer Lab is backed by a $500 Million collaboration with Roche, the biggest maker of cancer drugs, and $24 million in VC money.
Sal Daher, CFA, together with other angels, is an investor in SQZ Biotech. To learn more about investing alongside Sal and his colleagues in this type of startup please enter your email address:
Investments in Startups are Inherently Risky. Such investments should only be undertaken by financially sophisticated persons who are accredited investors as defined under US securities laws and who are capable of bearing the risks involved. Do seek independent investment advice in making your decision to invest. We do not provide investment advice.
LISTEN TO SAL’S INTERVIEW OF ARMON SHAREI, CEO OF SQZ BIOTECH HERE
CURRENT PODCAST EPISODE
New Podcast Episodes Released Every Other Wednesday.
Coming from a family of lawyers in Italy, Laura Indolfi was an unlikely candidate to found a tech startup. Yet, her love of engineering and fascination with materials took her to the storied labs at MIT led by Elazer Edelman and Bob Langer. Her startup, PanTher Therapeutics is using off-the-shelf cancer drugs and biomaterials to create a new way to treat cancers that are really hard to treat such as pancreatic cancer, Laura’s first target. Don’t miss this lively interview with a stellar founder.
New episodes released every Wednesday. Subscribe to our podcast on iTunes to make certain you never miss an episode: